Setmelanotide for controlling weight and hunger in Bardet-Biedl syndrome

Affiliations

¹ Centre de Référence Maladies Rares PRADORT, Hôpital des Enfants, CHU Toulouse, Université Toulouse III, Toulouse, France; Infinity, INSERM UMR 1291-CNRS UMR 5051, Université Toulouse III, Toulouse, France. Electronic address: tauber.mt@chu-toulouse.fr.

Comment

Maithe Tauber. Lancet Diabetes Endocrinol. 2022 Dec.

. 2022 Dec;10(12):829-830.

doi: 10.1016/S2213-8587(22)00309-6. Epub 2022 Nov 7.

¹ Centre de Référence Maladies Rares PRADORT, Hôpital des Enfants, CHU Toulouse, Université Toulouse III, Toulouse, France; Infinity, INSERM UMR 1291-CNRS UMR 5051, Université Toulouse III, Toulouse, France. Electronic address: tauber.mt@chu-toulouse.fr.

No abstract available

Conflict of interest statement

I declare no competing interests.

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Haqq AM, et al. Lancet Diabetes Endocrinol. 2022 Dec;10(12):859-868. doi: 10.1016/S2213-8587(22)00277-7. Epub 2022 Nov 7. Lancet Diabetes Endocrinol. 2022. PMID: 36356613 Free PMC article. Clinical Trial.